Orexo Interim Report Q1 2023
Orexo reported its Q1 2023 financial results, with net revenues of SEK 158.8 million, slightly down from SEK 159.4 million in Q1 2022. The company experienced a significant EBITDA decline, reporting SEK -41.1 million compared to SEK 2.8 million last year. Net earnings also saw a loss of SEK -63.9 million, worse than the previous SEK -23.6 million. Despite stable ZUBSOLV® sales in both SEK and USD, operating expenses surged by 30.6%, totaling SEK 189.4 million. A New Drug Application for OX124 has been submitted to the FDA, but challenges in the packaging line require a resubmission planned for Q3 2023. Cash flow from operations stood at SEK -61.6 million, with cash reserves down to SEK 278.9 million.
- Stable ZUBSOLV® US sales in USD compared to Q4.
- Exploratory feasibility studies of amorphOX® initiated with international partners.
- NDA submitted for OX124, high-dose rescue medication for opioid overdose.
- EBITDA decreased to SEK -41.1 million, a decline of 1,567.9%.
- Net earnings reported a loss of SEK -63.9 million, worsening from previous losses.
- Operating expenses rose significantly by 30.6%, totaling SEK 189.4 million.
- Cash and invested funds decreased to SEK 278.9 million, down 36.3% from the previous year.
- FDA requested resubmission of NDA for OX124 due to packaging line issues.
UPPSALA,
Q1 2023 highlights
- Total net revenues of
SEK 158.8 m (159.4) - EBITDA of
SEK -41.1 m (2.8), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 20.9 m (32.2) - Net earnings of
SEK -63.9 m (-23.6) - US Pharma segment (ZUBSOLV® US) net revenues of
SEK 140.3 m (139.1), in local currencyUSD 13.5 m (14.8), US Pharma EBIT ofSEK 74.3 m (84.0) - Cash flow from operating activities of
SEK -61.6 m (-61.6), cash and invested funds ofSEK 278.9 m (437.8) - Earnings per share before and after dilution amounted to -1.86 (-0.69)
- Exploratory feasibility studies of amorphOX® initiated in collaboration with two international biopharmaceutical and vaccine companies
- New Drug Application (NDA) submitted with the FDA for OX124, high-dose rescue medication for opioid overdose
Important events after the end of the period
- Due to issues in the outsourced packaging line FDA has requested
Orexo to resubmit the NDA, which is planned to take place in Q3, 2023
SEK m, unless otherwise stated | 2023 | 2022 | % change | 2022 |
Net revenues | 158.8 | 159.4 | -0.4 % | 624.3 |
Cost of goods sold | -28.7 | -27.5 | 4.2 % | -102.6 |
Operating expenses | -189.4 | -145.1 | 30.6 % | -705.6 |
EBIT | -59.3 | -13.2 | 350.0 % | -183.9 |
EBIT margin | -37.4 % | -8.3 % | 29.1 % | -29.5 % |
EBITDA | -41.1 | 2.8 | -1,567.9 % | -115.2 |
Earnings per share, before dilution, SEK | -1.86 | -0.69 | 169.6 % | -5.17 |
Earnings per share, after dilution, SEK | -1.86 | -0.69 | 169.6 % | -5.17 |
Cash flow from operating activities | -61.6 | -61.6 | 0.0 % | -156.6 |
Cash and invested funds | 278.9 | 437.8 | -36.3 % | 351.9 |
Comments by the CEO, Nikolaj Sørensen
Navigating troubled waters
"As expected, the first quarter has been intensive for
For full CEO comments view the attached PDF
For further information, please contact
Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com.
Presentation
At
To attend via teleconference where you can ask questions verbally use this link:
https://conference.financialhearings.com/teleconference/?id=200679
When registered you will be provided phone numbers and a conference ID to access the conference.
To attend via webcast:
https://ir.financialhearings.com/orexo-q1-2023
Prior to the call presentation material will be available on Orexo´s website Investors/Reports/Audiocasts.
This information is information that
The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/orexo-interim-report-q1-2023-301809298.html
SOURCE
FAQ
What were Orexo's Q1 2023 net revenues?
What is the EBITDA reported by Orexo for Q1 2023?
What challenges did Orexo face regarding the FDA submission for OX124?
How much did Orexo's cash reserves decrease by in Q1 2023?